Preventing stroke in patients with atrial fibrillation
Related Experiment Video
Updated: Jun 11, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
1Yale Clinical Trials Office, Yale University School of Medicine, New Haven, Conn 06511, USA. Michael.Ezekowitz@yale.edu
Insights
Warfarin significantly reduces stroke risk in high-risk atrial fibrillation patients. Aspirin is effective for those with lower stroke risk, offering a tailored approach to prevention.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation affects a significant portion of the elderly population, increasing stroke risk.
- Stroke prevention in atrial fibrillation is a critical clinical challenge.
Purpose of the Study:
- To evaluate evidence for warfarin and aspirin in preventing stroke in atrial fibrillation patients.
- To synthesize data from randomized trials on antithrombotic therapy.
Main Methods:
- Systematic review of prospective, randomized trials (1966-1999).
- Inclusion of placebo-controlled studies, secondary prevention trials, and comparative studies.
- Analysis of warfarin monotherapy, aspirin monotherapy, and combination therapy.
Main Results:
- Stroke risk is heterogeneous, increasing with age and comorbidities like hypertension and diabetes.
- Warfarin use reduces stroke risk from 4.3-12%/year to 1.2-4%/year in high-risk patients.
- Low-risk patients (<65 years) have a 1%/year stroke risk without therapy.
Conclusions:
- Warfarin provides the most substantial stroke protection for high-risk atrial fibrillation patients.
- Aspirin demonstrates adequacy in managing stroke risk for low-risk populations.
Context:
Atrial fibrillation, a common disorder that affects nearly one sixth of the population aged 75 years and older, is a major risk factor for stroke.
Objectives:
To review and evaluate the evidence supporting the use of warfarin and/or aspirin for stroke prevention in patients with atrial fibrillation.
Data Sources:
Prospective, randomized trials of patients with atrial fibrillation evaluating either warfarin or aspirin or both, from MEDLINE from January 1, 1966, to February 23, 1999.
Study Selection:
Five primary prevention placebo-controlled studies, which had been formally pooled, 1 study evaluating secondary prevention of stroke, 1 study comparing warfarin with aspirin, and 3 studies of warfarin in combination with aspirin were identified.
Data Synthesis:
The risk of developing stroke is heterogeneous and increases with each decade above 65 years; history of high blood pressure, diabetes mellitus, previous transient ischemic attack, or stroke; poor ventricular function; and in women older than 75 years. For patients younger than 65 years, without risk factors, and not receiving antithrombotic therapy, the risk of stroke is 1%/y; those without risk factors between the ages of 65 and 75 years have a risk of 1.1%/y if taking warfarin and 1.4%/y if taking aspirin. For all other patients, stroke risk is reduced from an untreated rate of between 4.3%/y and more than 12%/y to a rate of 1.2%/y to 4%/y with warfarin use.
Conclusion:
The protection afforded by warfarin is most pronounced in patients at the highest risk for stroke, while aspirin treatment seems adequate in low-risk populations.
More Related Videos
Related Concept Videos
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:25Pericarditis IV: Nursing Management
01:20Rheumatic Heart Disease IV: Nursing Management
01:26Heart Failure III: Clinical Manifestations
01:30Heart Failure VII: Nursing Interventions
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy